Xeljanz meets psoriasis endpoints but potential looks limited
This article was originally published in Scrip
Executive Summary
Pfizer has released positive top-line data for its JAK inihitor Xeljanz (tofacitinib) in the additional indication of plaque psoriasis in two further studies from its five-trial Phase III program, but a US filing is not likely until early next year.